DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Etrolizumab
Etrolizumab
Recent Advances in Inflammatory Bowel Disease: Mucosal Immune
HY 2021 Results
Immunfarmakológia Immunfarmakológia
(12) Patent Application Publication (10) Pub. No.: US 2017/0172932 A1 Peyman (43) Pub
Novel Therapies for Eosinophilic Disorders
Roche Investor Presentation Oppenheimer 23Rd Annual
Minutes PDCO 25-28 February 2020
Microbiota and Drug Response in Inflammatory Bowel Disease
Biological Treatments in Inflammatory Bowel Disease: a Complex Mix Of
INN Working Document 05.179 Update 2011
The Current State of the Art for Biological Therapies and New Small Molecules in Inflammatory Bowel Disease
A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum
NETTER, Jr., Robert, C. Et Al.; Dann, Dorf- (21) International Application
Highlights from the 2019 Advances in Inflammatory Bowel Diseases
211 the Impact of Biological Interventions on Health-Related Quality of Life in Adults with Crohn's Disease
Therapeutic Interventions in Severe Asthma Giorgio Walter Canonica1*, Gianenrico Senna2, Patrick D
New Targets in Inflammatory Bowel Disease Therapy: 2021
(INN) for Biological and Biotechnological Substances
Top View
Roche Investor Day 2012 Workshop Gred
New Targets for Mucosal Healing and Therapy in Inflammatory Bowel Diseases
Crohn's Disease Disease Coverage
Evaluatepharma® World Preview 2018, Outlook to 2024
A Randomised Phase I Study of Etrolizumab (Rhumab Β7) In
Roche Template
The Role of Biologics Agent in the Treatment of In.Ammatory Bowel
UCSF Colitis and Crohn's Disease Center (Clinical)
Vaccination in Immunosuppressed Adults ASID Adult Immunisation Workshop 9 May 2018
Pipeline Drug List Drug Information Pharmacist
Integrins As Therapeutic Targets: Successes and Cancers
( 12 ) United States Patent
Roche Provides Update on Phase III Studies of Etrolizumab in People
Phase III, Randomized, Double-Blind, Double-Dummy, Placebo
Etrolizumab for Crohn's Disease
IBD Treatments on the Horizon
A View Into Upcoming Specialty & Traditional Drugs
Etiology and Management of Lack Or Loss of Response to Anti–Tumor Necrosis Factor Therapy in Patients with Inflammatory Bowel Disease